A Phase 2 interventional study of Rivaroxaban (Xarelto, BAY59-7939) in Venous Thromboembolism, sponsored by Bayer. Completed at 29 sites in 15 countries. Open to participants aged 6 Months to 5 Years. Per ClinicalTrials.gov, last updated 2018-08-21.
Sponsored by Bayer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies testing rivaroxaban in Venous Thromboembolism — 18 open to participants now, 18 under way, 6 of them phase 3. Rivaroxaban · Venous Thromboembolism.
Among the 61 studies testing rivaroxaban in Venous Thromboembolism, this one is the 52nd largest by enrollment, is one of 2 that started in 2015, is one of 9 in phase 2, and was the 21st registered.
713 studies on the registry are indexed under Venous Thromboembolism; 147 are open to participants now.
Browse Venous Thromboembolism studies →18 of the 61 studies testing rivaroxaban in Venous Thromboembolism are open now, in 12 countries. Recruiting first, the newest first:
Military Hospital of Tunis · Sites in Tunisia
Ages 18–80
Wolfson Medical Center · Sites in Israel
Ages 18–50 · Women only
Mayo Hospital Lahore · Sites in Pakistan
Ages 18–80
Thomas Jefferson University · Sites in United States
Ages 18+ · Women only
Medical University of Gdansk · Sites in Poland
Ages 18+
By country, each count listing its studies:
Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: 6 Months to 5 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 29 · Phase 4 12
First in 2004; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is below the median of 241 across 402 interventional studies indexed under Venous Thromboembolism.
Median enrollment 272 across the 61 interventional studies. Of the 40 that completed or were terminated, 14 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 61 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
39 studies in Venous Thromboembolism by Bayer: 1 open now, 2 under way, none of them phase 3. Of 35 finished, 6 (17%) have results posted.
Among the 39 studies in Venous Thromboembolism by Bayer, this one is the 16th largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2015, is one of 6 in phase 2, and was the 22nd registered.
Bayer’s Venous Thromboembolism studies by the year they started, since 2004.
8 of the studies testing rivaroxaban in Venous Thromboembolism that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05029063Phase 3Ottawa Hospital Research InstitutePrimary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters | 2026-12 |
| NCT07228663Phase 3McMaster UniversityHip Fracture Surgery Arterial and Venous Thrombotic Events Prevention | 2027-07-01 |
| NCT06580223Phase 3Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma | 2027-09-01 |
| NCT04874428Insel Gruppe AG, University Hospital BernDirect Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis | 2026-12 |
| NCT07907211Chen LijuanAspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma | 2026-12-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 61 studies testing rivaroxaban in Venous Thromboembolism, from their registry updates:
Among Bayer’s 39 in Venous Thromboembolism:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to find out whether rivaroxaban is safe to use in children and how long it stays in the body. Safety will be assessed by looking at the incidence and types of bleeding events. There will also be a check for worsening of blood clots.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Age and body weight-adjusted twice daily dosing of rivaroxaban to achieve a similar exposure as that observed in adults treated for venous thromboembolism (VTE) with 20 mg rivaroxaban once daily
Drug: Rivaroxaban (Xarelto, BAY59-7939)
With age and body-weight adjusted twice daily dosing of rivaroxaban as Oral Suspension to achieve a similar exposure as that observed in adults treated with 20 mg rivaroxaban once daily, and no other anticoagulant
Number of Subjects With Major Bleeding and Clinically Relevant Non-Major Bleeding Events
Major bleeding is defined as overt bleeding and: * associated with a fall in hemoglobin of 2 gram/decilitre (g/dL) or more, or * leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults, or * occurring in a critical site, for example (e.g.) intracranial, intraspinal, intraocular, pericardial, intraarticular, intramuscular with compartment syndrome, retroperitoneal, or * contributing to death. Clinically relevant non-major bleeding is defined as overt bleeding not meeting the criteria for major bleeding, but associated with: * medical intervention, or * unscheduled contact (visit or telephone call) with a physician, or * cessation (temporary) of study treatment, or * discomfort for the child such as pain or * impairment of activities of daily life (such as loss of school days or hospitalization).
Time frame: During or within 2 days after stop of study treatment (up to 32 days)
Number of Subjects With Symptomatic Recurrent Venous Thromboembolism
Venous thromboembolism is the formation of a blood clot (thrombus) inside a blood vessel, obstructing the flow of blood through the circulatory system. The occurrence of recurrent venous thromboembolism was summarized by age group. Symptomatic recurrence, which is the composite of deep Vein Thrombosis (DVT), non-fatal Pulmonary Embolism (PE), and fatal PE of venous thrombosis, had to be documented using appropriate (repeat) imaging test.
Time frame: From start of the study treatment up to 30-days post study treatment period (approximately 60 days)
Number of Subjects With Asymptomatic Deterioration in Thrombotic Burden on Repeat Imaging
The occurrence of asymptomatic deterioration in thrombotic burden was summarized by age group. At the end of the 30-day treatment period, a repeat imaging of the thrombus was performed. The images of the index event and repeat imaging were adjudicated by the central independent adjudication committee (CIAC). The thrombotic burden at the time of the index event was compared to the thrombotic burden at the time of repeat imaging. The outcome of the adjudication was classified as normalized, improved, no relevant change, deteriorated, or not evaluable. Due to missing repeated imaging, thrombotic burden assessments were not done in some subjects.
Time frame: At the end of the 30-day treatment period
Change From Baseline in Prothrombin Time at Specified Time Points
Prothrombin time is a global clotting test used for the assessment of the extrinsic pathway of the blood coagulation cascade. Day 30 (10-16 hours post-dose) was considered as a baseline.
Time frame: Day 1 (2.5-4 hours post-dose); Day 15 (2-8 hours post-dose); Day 30 (10-16 hours post-dose)
Change From Baseline in Activated Partial Thromboplastin Time at Specified Time Points
The Activated partial thromboplastin time (aPTT) is a screening test for the intrinsic pathway. Day 30 (10-16 hours post-dose) was considered as a baseline.
Time frame: Day 1 (2.5-4 hours post-dose); Day 15 (2-8 hours post-dose); Day 30 (10-16 hours post-dose)
Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Specified Time Points
Concentration of rivaroxaban in plasma was measured at Day 1, 15 and 30 at specified time points. In the below table, 'n' signifies those subjects who were evaluable for this measure at given time points for each group. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.
Time frame: Day 1 (30-90 minutes, 2.5-4 hours post-dose); Day 15 (2-8 hours post-dose) and Day 30 (10-16 hours post-dose)
Anti-factor Xa Values at Specified Time Points
The individual anti-Factor Xa activity was determined ex-vivo using a photometric method. The anti-factor Xa assay is designed to measure plasma heparin, low molecular weight heparin and other anticoagulants. In the below table, 'n' signifies those subjects who were evaluable for this measure at given time points for each group.
Time frame: Day 1 (2.5-4 hours post-dose); Day 15 (2-8 hours post-dose) and Day 30 (10-16 hours post-dose)
Study was conducted at 27 study centers in 14 countries: Australia, Austria, Brazil, Canada, Hungary, Israel, Italy, Japan, Netherlands, Russia, Spain, Switzerland, United Kingdom, and United States between 15 January 2015 (first subject first visit) and 05 April 2017 (last subject last visit).
| Milestone | Rivaroxaban, Suspension, BID, Age: 2-6 Years | Rivaroxaban Suspension, BID, Age: 6 Months-2 Years | Anticoagulants, Comparator, Age: 2-6 Years |
|---|---|---|---|
| Started | 25 | 15 | 6 |
| Completed | 23 | 14 | 6 |
| Not completed | 2 | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 |
Major bleeding is defined as overt bleeding and: * associated with a fall in hemoglobin of 2 gram/decilitre (g/dL) or more, or * leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults, or * occurring in a critical site, for example (e.g.) intracranial, intraspinal, intraocular, pericardial, intraarticular, intramuscular with compartment syndrome, retroperitoneal, or * contributing to death. Clinically relevant non-major bleeding is defined as overt bleeding not meeting the criteria for major bleeding, but associated with: * medical intervention, or * unscheduled contact (visit or telephone call) with a physician, or * cessation (temporary) of study treatment, or * discomfort for the child such as pain or * impairment of activities of daily life (such as loss of school days or hospitalization).
| Participants | Rivaroxaban, Suspension, BID, Age: 2-6 Years | Rivaroxaban Suspension, BID, Age: 6 Months-2 Years |
|---|---|---|
| Major bleeding events | 0 | 0 |
| Clinically relevant non-major bleeding events | 0 | 0 |
Venous thromboembolism is the formation of a blood clot (thrombus) inside a blood vessel, obstructing the flow of blood through the circulatory system. The occurrence of recurrent venous thromboembolism was summarized by age group. Symptomatic recurrence, which is the composite of deep Vein Thrombosis (DVT), non-fatal Pulmonary Embolism (PE), and fatal PE of venous thrombosis, had to be documented using appropriate (repeat) imaging test.
| Participants | Rivaroxaban, Suspension, BID, Age: 2-6 Years | Rivaroxaban Suspension, BID, Age: 6 Months-2 Years |
|---|---|---|
| Number of Subjects With Symptomatic Recurrent Venous Thromboembolism | 0 | 0 |
The occurrence of asymptomatic deterioration in thrombotic burden was summarized by age group. At the end of the 30-day treatment period, a repeat imaging of the thrombus was performed. The images of the index event and repeat imaging were adjudicated by the central independent adjudication committee (CIAC). The thrombotic burden at the time of the index event was compared to the thrombotic burden at the time of repeat imaging. The outcome of the adjudication was classified as normalized, improved, no relevant change, deteriorated, or not evaluable. Due to missing repeated imaging, thrombotic burden assessments were not done in some subjects.
| Participants | Rivaroxaban, Suspension, BID, Age: 2-6 Years | Rivaroxaban Suspension, BID, Age: 6 Months-2 Years |
|---|---|---|
| Normalized | 6 | 4 |
| Improved | 15 | 4 |
| No relevant change | 1 | 3 |
| Deteriorated | 0 | 0 |
| Not evaluable | 0 | 0 |
| Not available | 0 | 0 |
| Missing | 3 | 4 |
Prothrombin time is a global clotting test used for the assessment of the extrinsic pathway of the blood coagulation cascade. Day 30 (10-16 hours post-dose) was considered as a baseline.
| Seconds | Rivaroxaban, Suspension, BID, Age: 2-6 Years | Rivaroxaban Suspension, BID, Age: 6 Months-2 Years |
|---|---|---|
| Day 1: 2.5-4 hours post-dose | 2.777 ± 4.845 | 2.514 ± 3.53 |
| Day 15: 2-8 hours post-dose | 2.586 ± 2.387 | 4.764 ± 4.738 |
The Activated partial thromboplastin time (aPTT) is a screening test for the intrinsic pathway. Day 30 (10-16 hours post-dose) was considered as a baseline.
| Seconds | Rivaroxaban, Suspension, BID, Age: 2-6 Years | Rivaroxaban Suspension, BID, Age: 6 Months-2 Years |
|---|---|---|
| Day 1: 2.5-4 hours post-dose | 6.455 ± 17.036 | -3.479 ± 40.443 |
| Day 15: 2-8 hours post-dose | 2.814 ± 6.375 | 21 ± 66.761 |
Concentration of rivaroxaban in plasma was measured at Day 1, 15 and 30 at specified time points. In the below table, 'n' signifies those subjects who were evaluable for this measure at given time points for each group. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.
| microgram per liter (mcg/L) | Rivaroxaban, Suspension, BID, Age: 2-6 Years | Rivaroxaban Suspension, BID, Age: 6 Months-2 Years |
|---|---|---|
| Day 1: 30-90 minutes post-dose | 72.8494 ± 153.76 | 68.0072 ± 160.77 |
| Day 1: 2.5-4 hours post-dose | 108.6053 ± 58.18 | 76.5371 ± 112.91 |
| Day 15: 2-8 hours post-dose | 112.3578 ± 46.37 | 61.3817 ± 451.46 |
| Day 30: 10-16 hours post-dose | 19.8714 ± 189.49 | 5.9545 ± 354.51 |
The individual anti-Factor Xa activity was determined ex-vivo using a photometric method. The anti-factor Xa assay is designed to measure plasma heparin, low molecular weight heparin and other anticoagulants. In the below table, 'n' signifies those subjects who were evaluable for this measure at given time points for each group.
| microgram per liter (mcg/L) | Rivaroxaban, Suspension, BID, Age: 2-6 Years | Rivaroxaban Suspension, BID, Age: 6 Months-2 Years |
|---|---|---|
| Day 1: 2.5-4 hours post-dose | 128.457 ± 69.615 | 87.831 ± 84.178 |
| Day 15: 2-8 hours post-dose | 103.105 ± 58.343 | 131.369 ± 96.489 |
| Day 30: 10-16 hours post-dose | 19.069 ± 17.463 | 16.952 ± 19.725 |
Collected over From start of study drug administration until 30 day post study treatment (approximately 60 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rivaroxaban BID (Suspension) (2 - 6 Years Group) | 0/25 (0%) | 0/25 (0%) | 14/25 (56%) |
| Rivaroxaban BID (Suspension) (6 Months - 2 Years Group) | 0/15 (0%) | 2/15 (13.3%) | 11/15 (73.3%) |
| Anticoagulants, Comparator (2 - 6 Years Group) | 0/6 (0%) | 1/6 (16.7%) | 3/6 (50%) |
| Event | Rivaroxaban BID (Suspension) (2 - 6 Years Group) | Rivaroxaban BID (Suspension) (6 Months - 2 Years Group) | Anticoagulants, Comparator (2 - 6 Years Group) |
|---|---|---|---|
| Optic atrophyEye disorders | 0/25 | 0/15 | 1/6 |
| HeadacheNervous system disorders | 0/25 | 0/15 | 1/6 |
| PyrexiaGeneral disorders | 0/25 | 1/15 | 0/6 |
| Respiratory disorderRespiratory, thoracic and mediastinal disorders | 0/25 | 1/15 | 0/6 |
| Event | Rivaroxaban BID (Suspension) (2 - 6 Years Group) | Rivaroxaban BID (Suspension) (6 Months - 2 Years Group) | Anticoagulants, Comparator (2 - 6 Years Group) |
|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 1/25 | 1/15 | 1/6 |
| NeutropeniaBlood and lymphatic system disorders | 0/25 | 1/15 | 1/6 |
| HaematocheziaGastrointestinal disorders | 0/25 | 0/15 | 1/6 |
| Rectal haemorrhageGastrointestinal disorders | 0/25 | 0/15 | 1/6 |
| GastroenteritisInfections and infestations | 0/25 | 0/15 | 1/6 |
| Viral upper respiratory tract infectionInfections and infestations | 3/25 | 0/15 | 1/6 |
| Blood fibrinogen decreasedInvestigations | 0/25 | 0/15 | 1/6 |
| Platelet count decreasedInvestigations | 0/25 | 0/15 | 1/6 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 0/25 | 0/15 | 1/6 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 0/25 | 0/15 | 1/6 |
| Age, Continuous(years) | Rivaroxaban, Suspension, BID, Age: 2-6 Years | Rivaroxaban Suspension, BID, Age: 6 Months-2 Years | Anticoagulants, Comparator, Age: 2-6 Years | Total |
|---|---|---|---|---|
| Mean | 3.77 ± 1.03 | 1.26 ± 0.45 | 3.67 ± 0.82 | 2.94 ± 1.45 |
| Sex: Female, Male(Participants) | Rivaroxaban, Suspension, BID, Age: 2-6 Years | Rivaroxaban Suspension, BID, Age: 6 Months-2 Years | Anticoagulants, Comparator, Age: 2-6 Years | Total |
|---|---|---|---|---|
| Female | 12 | 9 | 3 | 24 |
| Male | 13 | 6 | 3 | 22 |
| Race (NIH/OMB)(Participants) | Rivaroxaban, Suspension, BID, Age: 2-6 Years | Rivaroxaban Suspension, BID, Age: 6 Months-2 Years | Anticoagulants, Comparator, Age: 2-6 Years | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 0 | 3 |
| White | 23 | 10 | 6 | 39 |
| More than one race | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 1 | 1 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2015 to primary completion in Apr 2017, 26 months.
Results were first posted in Jun 2018, 1 year 2 months after primary completion.
Of 27 phase 2 interventional studies under Venous Thromboembolism, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 50. This study's 26 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rivaroxaban